June 24, 2014
A novel assay for the detection and characterization of the removal of cellular regulators as a diagnostic tool for hematological cancers that will respond to treatment by a repurposed therapeutic.
This assay will allow for individualized medicine by testing individual patient blood samples. Furthermore, this technology allows for the reprogramming of cancer cells, a technique that can be applied to the treatment of malignancies on a patient-by-patient basis.
The metastasis of tumors in cancer patients allows cancerous cells to spread from one part of the body to another. Metastatic tumors can cause a wide range of problems, many of which are highly severe and even life-threatening. Cancer that becomes metastatic becomes much more difficult to treat, as the metastatic tumors can be difficult to detect early on and provide further complications for the patient. One of the main causes of tumor initiation, progression, and metastasis is a loss of apoptosis of tumor cells. The cessation of cancer cell death results in the spread and enlargement of tumors. Previously, explanations for this phenomenon have been rare and tentative. The ability to reverse the loss of apoptosis—and to reinitiate apoptosis in cancer cells—would provide a novel and effective treatment method for patients suffering from malignant, progressing tumors. Such a treatment could even result in the diminishment of tumors by promoting continued death of cancerous cells.
Researchers at the University of New Mexico have developed a novel assay for the detection and characterization of the removal of cellular regulators as a diagnostic tool for hematological cancers that will respond to treatment by a repurposed therapeutic. This assay will allow for individualized medicine by testing individual patient blood samples. Furthermore, this technology allows for the reprogramming of cancer cells, a technique that can be applied to the treatment of malignancies on a patient-by-patient basis.
Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia
As the technology-transfer and economic-development organization for the University of New Mexico, STC.UNM protects and commercializes technologies developed at the University of New Mexico (UNM) by filing patents and copyrights and transferring the technologies to the marketplace. We connect the business communication (companies, entrepreneurs and investors) to these UNM technologies for licensing opportunities and the creation of startup companies. Visit www.stc.unm.edu.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
promoting continued death
potential therapeutic agents
technology description researchers
effective treatment method
cancer cells—would provide
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium